No recent analyst price targets found for PULM.
Latest News for PULM
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX FRAMINGHAM, Mass., Aug. 13, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™…
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--PULM, SLP, OLN, and HUN
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--PULM, SLP, OLN, and HUN PR Newswire
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PULM.
U.S. House Trading
No House trades found for PULM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.